NO20062139L - Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister - Google Patents

Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister

Info

Publication number
NO20062139L
NO20062139L NO20062139A NO20062139A NO20062139L NO 20062139 L NO20062139 L NO 20062139L NO 20062139 A NO20062139 A NO 20062139A NO 20062139 A NO20062139 A NO 20062139A NO 20062139 L NO20062139 L NO 20062139L
Authority
NO
Norway
Prior art keywords
dihydrobenzofuranyl
agonists
compounds
5ht2c agonists
alkanamine derivatives
Prior art date
Application number
NO20062139A
Other languages
English (en)
Inventor
Gary Paul Stack
Dahui Zhou
Jonathan Laird Gross
Marla Jean Williams
Hong Gao
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34576747&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062139(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20062139L publication Critical patent/NO20062139L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Det tilveiebringes forbindelser med formel (I), eller farmasøytisk akseptable salter derav: Formel (I) som er agonister eller delvis agonister til 2C-undertypen av serotonin-reseptorer i hjernen. Forbindelsene, og preparater inneholdende forbindelsene, kan anvendes for å behandle en rekke lidelser i sentralnervesystemet, så som schizofreni.
NO20062139A 2003-10-24 2006-05-12 Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister NO20062139L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51445403P 2003-10-24 2003-10-24
US10/970,714 US7435837B2 (en) 2003-10-24 2004-10-21 Dihydrobenzofuranyl alkanamine derivatives and methods for using same
PCT/US2004/035280 WO2005044812A1 (en) 2003-10-24 2004-10-22 Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists

Publications (1)

Publication Number Publication Date
NO20062139L true NO20062139L (no) 2006-07-21

Family

ID=34576747

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062139A NO20062139L (no) 2003-10-24 2006-05-12 Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister

Country Status (20)

Country Link
US (2) US7435837B2 (no)
EP (1) EP1675840A1 (no)
JP (1) JP2007509174A (no)
KR (1) KR20060092257A (no)
CN (1) CN1997635A (no)
AR (1) AR046309A1 (no)
AU (1) AU2004287809A1 (no)
BR (1) BRPI0415657A (no)
CA (1) CA2542878A1 (no)
CR (1) CR8349A (no)
EC (1) ECSP066520A (no)
IL (1) IL174953A0 (no)
MX (1) MXPA06004409A (no)
NO (1) NO20062139L (no)
PA (1) PA8615701A1 (no)
PE (1) PE20050482A1 (no)
RU (1) RU2006117789A (no)
TW (1) TW200526615A (no)
WO (1) WO2005044812A1 (no)
ZA (1) ZA200603233B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
WO2005082863A2 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag 1,4 diaryl-dihydropyrimidin-2 ones and their use as a human neutrophil elastase inhibitors
JP4825194B2 (ja) * 2004-02-26 2011-11-30 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジアリール−ジヒドロピリミジン−２−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用
WO2006000902A1 (en) * 2004-06-25 2006-01-05 Pfizer Products Inc. Dihydrobenzofuran compounds and uses thereof
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
BRPI0609988A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp derivados de diidrobenzofurano e usos dos mesmos
PE20061297A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
CN101175740A (zh) * 2005-04-22 2008-05-07 惠氏公司 二氢苯并呋喃衍生物和其用途
JP2008538581A (ja) * 2005-04-22 2008-10-30 ワイス ｛［（２ｒ）−７−（２，６−ジクロロフェニル）−５−フルオロ−２，３−ジヒドロ−１−ベンゾフラン−２−イル］メチル｝アミン塩酸塩の結晶形態
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
EP1871355A1 (en) * 2005-04-22 2008-01-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
EP1898895A2 (en) * 2005-04-22 2008-03-19 Wyeth Treatment of drug abuse
JP2008538578A (ja) * 2005-04-22 2008-10-30 ワイス 疼痛の治療
GT200600161A (es) * 2005-04-22 2007-03-14 Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
CA2606064A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
WO2007112065A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CL2007003043A1 (es) * 2006-10-24 2008-05-30 Wyeth Corp Compuestos derivados de cromano; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y ansiedad entre otros.
PE20081139A1 (es) * 2006-10-25 2008-09-18 Wyeth Corp Derivados de cromano, su sintesis e intermediarios
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
UA107657C2 (uk) * 2009-03-10 2015-02-10 Такеда Фармасьютікал Компані Лімітед Похідні бензофурану
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US8492591B2 (en) 2010-02-04 2013-07-23 The Board Of Trustees Of The University Of Illinois Highly selective 5-HT(2C) receptor agonists that show anti-psychotic effects with antagonist activity at the 5-HT(2B) receptor
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
RU2549543C2 (ru) 2010-12-21 2015-04-27 Колгейт-Палмолив Компани Галогенированные бифенолы в качестве антибактериальных средств
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2016123164A1 (en) 2015-01-29 2016-08-04 The Board Of Trustees Of The University Of Illinois Cyclopropylmethanamines as selective 5-ht(2c) receptor agonists
CN108084125B (zh) * 2016-11-23 2020-08-18 华东理工大学 苯并杂环烷基胺类化合物及其用途
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
EP3878447A1 (en) 2020-03-11 2021-09-15 InterAx Biotech AG Beta adrenergic receptor antagonists

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200892A (en) 1966-10-27 1970-08-05 Ward Blenkinsop & Co Ltd Production of 2-aminomethyl-2,3-dihydrobenzofurans
US3513239A (en) * 1967-03-15 1970-05-19 Smithkline Corp Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith
US3826835A (en) * 1971-01-08 1974-07-30 Ciba Geigy Corp 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics
US4205080A (en) * 1977-07-21 1980-05-27 Shell Oil Company 2,3-Dihydro benzofuran carboxamides
US4237144A (en) * 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-2,6,7-trisubstituted-5-acylbenzofurans
GB8515388D0 (en) * 1985-06-18 1985-07-17 Ici Plc Heterocyclic compounds
US4873325A (en) * 1986-06-25 1989-10-10 Uop Process for the production of amides
FR2601950B1 (fr) 1986-07-22 1988-11-10 Cerm Cent Europ Rech Mauvernay N,n-dimethyl-n'-benzoyl-n' ((2,3-dihydro) benzofuran-2-yl-methyl) 1,3-propanediamine, preparation et compositions pharmaceutiques les contenant
US4992464A (en) * 1987-02-10 1991-02-12 Abbott Laboratories Heteroaryl N-hydroxy amides and ureas with polar substituents as 5-lipoxygenase inhibitors
US5147888A (en) * 1989-12-04 1992-09-15 G. D. Searle & Co. N-terminal indolyy indolylalkylaminodiol β-amino acid derivatives
US5171751A (en) * 1989-12-04 1992-12-15 G. D. Searle & Co. Benzofuran/benzofuranalkyl-N-terminal amino hydroxy
US5110825A (en) 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
IT1239946B (it) 1990-03-12 1993-11-27 Biomedica Foscama Industria Chimicofarmaceutica Procedimento per la sintesi degli acidi 5-acilossi e 5-alcossi-2,3-diidro-4,6,7-trimetil-2-(rs)-benzofuranacetici
US5100825A (en) * 1990-11-16 1992-03-31 Micron Technology, Inc. Method of making stacked surrounding reintrant wall capacitor
IL101785A0 (en) 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0530149A1 (de) 1991-08-30 1993-03-03 Ciba-Geigy Ag Schädlingsbekämpfungsmittel
JP3153335B2 (ja) 1992-06-05 2001-04-09 興和株式会社 キノリン誘導体又はその塩
EP0606489A4 (en) * 1992-07-03 1995-01-25 Kumiai Chemical Industry Co CONDENSED HETEROCYCLIC DERIVATIVE AND HERBICIDE.
JP3283114B2 (ja) * 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
EP0664792B1 (en) * 1992-10-14 2000-01-05 Merck & Co. Inc. Fibrinogen receptor antagonists
US5292900A (en) * 1992-12-18 1994-03-08 Abbott Laboratories O-substituted N-hydroxyurea derivatives
US5612356A (en) * 1992-12-28 1997-03-18 Eisai Co., Ltd. Heterocycle-containing carbonic acid derivatives
AU7366794A (en) * 1993-07-14 1995-02-13 Smithkline Beecham Corporation Synthesis of acid addition salts of hydroxylamines
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US5350748A (en) * 1993-08-18 1994-09-27 Warner-Lambert Company 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion
JP2999669B2 (ja) 1993-08-24 2000-01-17 株式会社三和化学研究所 ベンゾ［ｂ］フランカルボキサミド誘導体、その製法及び用途
AU694212B2 (en) * 1994-04-28 1998-07-16 Merck Sharp & Dohme Limited Benzofuran derivatives as d4 receptor antagonists
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
KR100186661B1 (ko) * 1994-07-07 1999-05-01 유미꾸라 레이이찌 신규 2,3-디히드로벤조푸란 유도체, 그의 제조 방법 및 용도
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
PT707007E (pt) * 1994-10-14 2002-06-28 Merck Patent Gmbh Derivados amino(tio)eter como agentes activos no snc
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
EP0846109B1 (en) * 1995-08-21 2002-07-24 Takeda Chemical Industries, Ltd. Quinone compound, its production and use
GB9517559D0 (en) * 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
US5684041A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5955495A (en) * 1996-05-03 1999-09-21 Hoffmann-La Roche Inc. Method of treating diseases of the CNS
EP0846683B1 (en) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxy-piperidine derivatives
PT971878E (pt) * 1997-02-27 2008-07-08 Takeda Pharmaceutical Compostos de amina, sua produção e utilização como inibidores da produção de amilóide beta
FR2772766B1 (fr) * 1997-12-24 2000-06-30 Adir Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19909760B4 (de) 1998-04-17 2015-05-21 Merck Patent Gmbh Benzofuran-Derivate
US6251936B1 (en) * 1998-05-12 2001-06-26 American Home Products Corporation Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
AU753691B2 (en) * 1998-06-18 2002-10-24 Novartis Ag Benzazole compounds and their use
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US6255324B1 (en) * 1998-11-25 2001-07-03 Ned D. Heindel Amino-and mercurio-substituted 4′,5'-dihydropsoralens and therapeutical uses thereof
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6410562B1 (en) * 1998-12-18 2002-06-25 Eli Lilly And Company Hypoglycemic imidazoline compounds
JP2002535396A (ja) * 1999-01-27 2002-10-22 イーライ・リリー・アンド・カンパニー セロトニン（５−ｈｔ（２ｃ））アゴニストとしてのアミノアルキルベンゾフラン類
EP1211253B1 (en) 1999-08-20 2004-10-13 Takeda Chemical Industries, Ltd. Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents
DE10044091A1 (de) * 2000-09-07 2002-04-04 Merck Patent Gmbh Chromanonderivate
EP1377549A1 (en) * 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US20020183309A1 (en) * 2001-03-16 2002-12-05 Cowart Marlon D. Novel amines as histamine-3 receptor ligands and their therapeutic applications
US6969730B2 (en) * 2001-03-16 2005-11-29 Abbott Laboratories Amines as histamine-3 receptor ligands and their therapeutic applications
US20020177589A1 (en) * 2001-03-16 2002-11-28 Cowart Marlon D. Novel amines as histamine-3 receptor ligands and their therapeutic applications
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
AU2002318206A1 (en) * 2001-08-14 2003-03-03 Jolie Anne Bastian 3-substituted oxindole beta-3 agonists
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
US6569894B1 (en) * 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
CA2461381A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
WO2003031439A1 (en) * 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US20030105830A1 (en) * 2001-12-03 2003-06-05 Duc Pham Scalable network media access controller and methods
US20030134835A1 (en) * 2002-01-11 2003-07-17 Arthur Hancock Histamine-3 receptor ligands for diabetes conditions
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
DE10205274A1 (de) * 2002-02-08 2003-08-21 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen enthaltend neben Anticholinergika heterocyclische Verbindungen
EP1348708A1 (en) 2002-02-28 2003-10-01 Sanofi-Synthelabo Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
JP2005521711A (ja) * 2002-03-29 2005-07-21 中外製薬株式会社 呼吸器疾病の予防または治療のための医薬組成物
KR20030084444A (ko) * 2002-04-26 2003-11-01 주식회사 파나진 Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
US20040009976A1 (en) * 2002-04-30 2004-01-15 Kumiko Takeuchi Hypoglycemic imidazoline compounds
IL165589A (en) 2002-06-14 2012-04-30 Toyama Chemical Co Ltd Pharmaceutical preparation to improve brain function and use
WO2004045534A2 (en) * 2002-11-15 2004-06-03 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
US7098241B2 (en) * 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
ES2353306T3 (es) * 2003-08-01 2011-03-01 Chugai Seiyaku Kabushiki Kaisha Compuestos heterocíclicos útiles como inhibidores de la malonil-coa-descarboxilasa.
US7795242B2 (en) * 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005063240A1 (en) * 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
CN102091068B (zh) * 2004-05-03 2012-09-19 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物
EP1600447A1 (en) 2004-05-28 2005-11-30 Neuropharma S.A.U. Butyrylcholinesterase selective inhibitors
AU2005265270B2 (en) * 2004-06-22 2011-09-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
EP1871759A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Benzodioxane and benzodioxolane derivatives and uses thereof
JP2008538581A (ja) * 2005-04-22 2008-10-30 ワイス ｛［（２ｒ）−７−（２，６−ジクロロフェニル）−５−フルオロ−２，３−ジヒドロ−１−ベンゾフラン−２−イル］メチル｝アミン塩酸塩の結晶形態
GT200600161A (es) * 2005-04-22 2007-03-14 Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
JP2008538578A (ja) * 2005-04-22 2008-10-30 ワイス 疼痛の治療
EP1898895A2 (en) * 2005-04-22 2008-03-19 Wyeth Treatment of drug abuse
CN101175740A (zh) * 2005-04-22 2008-05-07 惠氏公司 二氢苯并呋喃衍生物和其用途
EP1871355A1 (en) * 2005-04-22 2008-01-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
BRPI0609988A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp derivados de diidrobenzofurano e usos dos mesmos
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
PE20061297A1 (es) * 2005-04-22 2006-12-24 Wyeth Corp Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
CA2606064A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function

Also Published As

Publication number Publication date
TW200526615A (en) 2005-08-16
AR046309A1 (es) 2005-11-30
EP1675840A1 (en) 2006-07-05
AU2004287809A1 (en) 2005-05-19
US20090082434A1 (en) 2009-03-26
RU2006117789A (ru) 2007-11-27
CA2542878A1 (en) 2005-05-19
JP2007509174A (ja) 2007-04-12
MXPA06004409A (es) 2007-01-26
WO2005044812A1 (en) 2005-05-19
CR8349A (es) 2007-06-06
PE20050482A1 (es) 2005-10-13
US7435837B2 (en) 2008-10-14
BRPI0415657A (pt) 2006-12-19
IL174953A0 (en) 2006-08-20
KR20060092257A (ko) 2006-08-22
PA8615701A1 (es) 2005-11-25
ECSP066520A (es) 2006-10-10
CN1997635A (zh) 2007-07-11
ZA200603233B (en) 2008-11-26
US20050143452A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
MX2007013021A (es) Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
WO2006050007A3 (en) Substituted indolizines and derivatives as cns agents
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
TW200716595A (en) Chromane and chromene derivatives and uses thereof
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
DE60322266D1 (de) N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
AP2002002481A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors.
NO20055977L (no) Nye benzimidazolderivater
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
WO2008020306A3 (en) Isoindole derivatives
NO20080033L (no) Kinolinderivater som NK3-antagonister
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
NO20075477L (no) Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application